• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cardlytics Announces Fourth Quarter and Full Year 2025 Financial Results

    3/4/26 4:02:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology
    Get the next $CDLX alert in real time by email

    Cardlytics, Inc. (NASDAQ:CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2025.

    "In 2025, we took several steps to reset our business and improve our financial health," said Amit Gupta, CEO of Cardlytics. "Going forward, we remain well positioned to execute our mandate and deliver for our partners and advertisers, even as we navigate a decrease in MQUs following the conclusion of our Bank of America campaigns in January. We are moving forward with sharper focus and discipline to control our own destiny by prioritizing our initiatives that build on our core fundamental strengths."

    "It has been reinvigorating to rejoin the Cardlytics team," said David Evans, CFO of Cardlytics. "I continue to believe in the strength and uniqueness of our platform. Leading up to this quarter, the business made several necessary decisions to right size our balance sheet to position the business for self-sustainability going forward. As such, we're taking a very focused, disciplined approach to execution and cost management in 2026."

    Fourth Quarter 2025 Financial Results

    • Total Revenue was $56.1 million, a decrease of 24.2% compared to $74.0 million in the fourth quarter of 2024.
    • Billings, a non-GAAP metric, was $94.1 million, a decrease of 19.0% compared to $116.3 million in the fourth quarter of 2024.
    • Adjusted Contribution, a non-GAAP metric, was $31.7 million, a decrease of 22.1% compared to $40.7 million in the fourth quarter of 2024.
    • Net Loss was $(8.3) million, or $(0.15) per share, based on 54.3 million weighted-average common shares outstanding, compared to a Net Loss of $(15.6) million, or $(0.31) per share, based on 51.0 million weighted-average common shares outstanding in the fourth quarter of 2024.
    • Adjusted EBITDA, a non-GAAP metric, was $8.5 million, an increase of $2.1 million compared to $6.4 million in the fourth quarter of 2024.
    • Adjusted Net Income, a non-GAAP metric, was $1.6 million, or $0.03 per diluted share, based on 54.3 million weighted-average common shares outstanding in the fourth quarter of 2025, compared to an Adjusted Net Income of $0.2 million, or $0.00 per diluted share, based on 51.0 million weighted-average common shares outstanding in the fourth quarter of 2024.
    • Net cash provided by operating activities was $13.0 million, an increase of $10.0 million compared to net cash provided by operating activities of $3.0 million in the fourth quarter of 2024.
    • Free Cash Flow, a non-GAAP metric, was $10.5 million, an increase of $11.9 million compared to $(1.5) million in the fourth quarter of 2024.

    Fiscal Year 2025 Financial Results

    • Total Revenue was $233.3 million, a decrease of 16.2% compared to $278.3 million in 2024.
    • Billings, a non-GAAP metric, was $385.0 million, a decrease of 13.3% compared to $443.8 million in 2024.
    • Adjusted Contribution, a non-GAAP metric, was $130.3 million, a decrease of 13.4% compared to $150.5 million in 2024.
    • Net Loss was $(103.5) million, or $(1.95) per share, based on 53.1 million weighted-average common shares outstanding, compared to a Net Loss of $(189.3) million, or $(3.91) per share, based on 48.4 million weighted-average common shares outstanding in 2024.
    • Adjusted EBITDA, a non-GAAP metric, was $10.1 million, an increase of $7.5 million compared to $2.5 million in 2024.
    • Adjusted Net Loss, a non-GAAP metric, was $(17.3) million, or $(0.33) per diluted share, based on 53.1 million weighted-average common shares outstanding in 2025, compared to an Adjusted Net Loss of $(18.9) million, or $(0.39) per diluted share, based on 48.4 million weighted-average common shares outstanding in 2024.
    • Net cash provided by/(used in) operating activities was $9.3 million, an increase of $18.1 million compared to $(8.8) million in 2024.
    • Free Cash Flow, a non-GAAP metric, was $(6.5) million an increase of $21.6 million compared to $(28.1) million in 2024.

    Key Metrics

    • Cardlytics MQUs in the quarter were 227.0 million, an increase of 18.4% compared to 191.7 million in the fourth quarter of 2024. For full year 2025, Cardlytics MQUs were 224.2 million, an increase of 17.7% compared to 190.5 million in 2024.
    • Cardlytics ACPU in the quarter was $0.12, a decrease of 35.0% compared to $0.18 in the fourth quarters for 2025 and 2024. For the full year 2025, Cardlytics ACPU was $0.50, a decrease of 25.4% compared to $0.67 in 2024.

    Definitions of MQUs and ACPU are included below under the caption "Non-GAAP Measures and Other Performance Metrics."

     

    CARDLYTICS, INC.

    SUMMARY OF GAAP AND NON-GAAP RESULTS (UNAUDITED)

    (Dollars in thousands)
     

     

     

    Three Months Ended

    December 31,

     

     

     

     

    2025

     

     

     

    2024

     

     

    Change %

    Billings(1)

    $

    94,136

     

     

    $

    116,279

     

     

    (19.0

    )%

    Consumer Incentives

     

    38,041

     

     

     

    42,283

     

     

    (10.0

    )%

    Revenue

     

    56,095

     

     

     

    73,996

     

     

    (24.2

    )%

    Partner Share and other third-party costs

     

    24,395

     

     

     

    33,285

     

     

    (26.7

    )%

    Adjusted Contribution(1)

     

    31,700

     

     

     

    40,711

     

     

    (22.1

    )%

    Delivery costs

     

    5,810

     

     

     

    7,979

     

     

    (27.2

    )%

    Gross Profit

    $

    25,890

     

     

    $

    32,732

     

     

    (20.9

    )%

    Net Loss

    $

    (8,250

    )

     

    $

    (15,590

    )

     

    (47.1

    )%

    Adjusted EBITDA(1)

    $

    8,534

     

     

    $

    6,398

     

     

    33.4

    %

     

     

     

     

     

     

    Adjusted Contribution

     

     

     

     

     

    % of Billings

     

    33.7

    %

     

     

    35.0

    %

     

     

    % of Revenue

     

    56.5

    %

     

     

    55.0

    %

     

     

    Adjusted EBITDA

     

     

     

     

     

    % of Billings

     

    9.1

    %

     

     

    5.5

    %

     

     

    % of Revenue

     

    15.2

    %

     

     

    8.6

    %

     

     

    (1)

    Billings, Adjusted Contribution and Adjusted EBITDA are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings "Reconciliation of GAAP Revenue to Billings," "Reconciliation of GAAP Gross Profit to Adjusted Contribution" and "Reconciliation of GAAP Net Loss to Adjusted EBITDA."

     
     

     

    Year Ended December 31,

     

     

     

    2025

     

     

     

    2024

     

     

    Change %

    Billings(1)

    $

    384,958

     

     

    $

    443,840

     

     

    (13.3

    )%

    Consumer Incentives

     

    151,685

     

     

     

    165,542

     

     

    (8.4

    )%

    Revenue

     

    233,273

     

     

     

    278,298

     

     

    (16.2

    )%

    Partner Share and other third-party costs

     

    102,949

     

     

     

    127,761

     

     

    (19.4

    )%

    Adjusted Contribution(1)

     

    130,324

     

     

     

    150,537

     

     

    (13.4

    )%

    Delivery costs

     

    25,711

     

     

     

    29,643

     

     

    (13.3

    )%

    Gross Profit

    $

    104,613

     

     

    $

    120,894

     

     

    (13.5

    )%

    Net Loss

    $

    (103,488

    )

     

    $

    (189,304

    )

     

    (45.3

    )%

    Adjusted EBITDA(1)

    $

    10,057

     

     

    $

    2,523

     

     

    298.6

    %

     

     

     

     

     

     

    Adjusted Contribution

     

     

     

     

     

    % of Billings

     

    33.9

    %

     

     

    33.9

    %

     

     

    % of Revenue

     

    55.9

    %

     

     

    54.1

    %

     

     

    Adjusted EBITDA

     

     

     

     

     

    % of Billings

     

    2.6

    %

     

     

    0.6

    %

     

     

    % of Revenue

     

    4.3

    %

     

     

    0.9

    %

     

     

    (1)

    Billings, Adjusted Contribution and Adjusted EBITDA are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings "Reconciliation of GAAP Revenue to Billings," "Reconciliation of GAAP Gross Profit to Adjusted Contribution" and "Reconciliation of GAAP Net Loss to Adjusted EBITDA."

     

    First Quarter 2026 Financial Expectations

    Cardlytics anticipates Billings, Revenue, Adjusted Contribution and Adjusted EBITDA to be in the following ranges (in millions, except for percentage change rates):

     

    Q1 2026 Guidance

     

    YoY Change

    Billings(1)

    $57.5 - $63.5

     

    (41%) - (35%)

    Revenue

    $35.0 - $40.0

     

    (43%) - (35%)

    Adjusted Contribution(2)

    $20.0 - $23.0

     

    (38%) - (29%)

    Adjusted EBITDA(2)

    ($7.5) - ($3.5)

     

    ($3.1) - $0.9

    (1)

    A reconciliation of Billings to GAAP Revenue on a forward-looking basis is presented below under the heading "Reconciliation of Forecasted GAAP Revenue to Billings."

    (2)

    A reconciliation of Adjusted Contribution to GAAP Gross Profit and a reconciliation of Adjusted EBITDA to GAAP Net Loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure. 

     

    Earnings Teleconference Information

    Cardlytics will discuss its fourth quarter and full year 2025 financial results during a teleconference today, March 4, 2026, at 5:00 PM ET / 2:00 PM PT. Following the completion of the call, a recorded replay of the webcast will be available on Cardlytics' website.

    About Cardlytics

    Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' first-party purchase data, that makes commerce smarter and more rewarding for everyone. We offer a range of solutions to help advertisers and publishers grow and strengthen customer loyalty. With visibility into approximately half of all card-based transactions in the U.S. and a quarter in the U.K., Cardlytics enables advertisers to engage consumers at scale and drive incremental sales through our industry-leading card-linked offer network. Publisher partners can enhance their platforms with relevant and personalized offers that improve the shopping experience for their customers. Learn more at www.cardlytics.com or follow us on LinkedIn.

    Cautionary Language Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements related to our growth opportunity, our ability to deliver stronger execution and shareholder value, our intention to strengthen our competitive position, enhance our product and tech capabilities and expand our network of partners and advertisers and our financial guidance for the first quarter of 2026. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," or variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control.

    Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: risks related to unfavorable conditions in the global economy and the industries that we serve; our quarterly operating results have fluctuated and may continue to vary from period to period; our ability to sustain our revenue growth and billings; risks related to our substantial dependence on our Cardlytics platform; risks related to our substantial dependence on JPMorgan Chase Bank, National Association ("Chase"), Wells Fargo Bank, National Association ("Wells Fargo"), American Express Travel Related Services Company, Inc. ("American Express") and a limited number of other financial institution ("FI") partners; risks related to our ability to maintain relationships with Chase and Wells Fargo; the amount and timing of budgets by marketers, which are affected by budget cycles, economic conditions and other factors; our ability to generate sufficient revenue to offset contractual commitments to FI partners; our ability to attract new partners, including FI partners, and maintain relationships with bank processors and digital banking providers; our ability to maintain relationships with marketers; our ability to adapt to changing market conditions, including our ability to adapt to changes in consumer habits, negotiate fee arrangements with new and existing partners and retailers, and develop and launch new services and features; our ability to consummate the closing of the Bridg sale and receipts of the proceeds therefrom; and other risks detailed in the "Risk Factors" section of our Form 10-K filed with the Securities and Exchange Commission on March 4, 2026 and in subsequent periodic reports that we file with the Securities and Exchange Commission. Past performance is not necessarily indicative of future results.

    The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    Non-GAAP Measures and Other Performance Metrics

    To supplement the financial measures presented in our press release and related conference call or webcast in accordance with generally accepted accounting principles in the United States ("GAAP"), we also present the following non-GAAP measures of financial performance in this press release: Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per share and Free Cash Flow, as well as certain other performance metrics, such as monthly qualified users ("MQUs") and adjusted contribution per user ("ACPU").

    A "non-GAAP financial measure" refers to a numerical measure of our historical or future financial performance or financial position that is included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in our financial statements. We provide certain non-GAAP measures as additional information relating to our operating results as a complement to results provided in accordance with GAAP. The non-GAAP financial information presented herein should be considered in conjunction with, and not as a substitute for or superior to, the financial information presented in accordance with GAAP and should not be considered a measure of liquidity. There are significant limitations associated with the use of non-GAAP financial measures. Further, these measures may differ from the non-GAAP information, even where similarly titled, used by other companies and therefore should not be used to compare our performance to that of other companies.

    We have presented Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per share as non-GAAP financial measures in this press release. Billings represents the gross amount billed to customers and marketers for services in order to generate revenue. Cardlytics platform Billings is recognized gross of both Consumer Incentives and Partner Share. Cardlytics platform GAAP Revenue is recognized net of Consumer Incentives and gross of Partner Share. Bridg platform Billings is the same as Bridg platform GAAP Revenue. Adjusted Contribution measures the degree by which revenue generated from our marketers exceeds the cost to obtain the purchase data and the digital advertising space from our partners. Adjusted Contribution demonstrates how incremental Revenue on our platforms generates incremental amounts to support our sales and marketing, research and development, general and administrative and other investments. Adjusted Contribution is calculated by taking our total Revenue less our Partner Share and other third-party costs. Adjusted Contribution does not take into account all costs associated with generating Revenue from advertising campaigns, including sales and marketing expenses, research and development expenses, general and administrative expenses and other expenses, which we do not take into consideration when making decisions on how to manage our advertising campaigns. Management views Adjusted Contribution as the most relevant metric to measure the financial performance as it reflects the dollars we keep after all of our partners are paid. Adjusted EBITDA represents our Net Loss before interest expense, net; depreciation and amortization; stock-based compensation expense; acquisition, integration and divestiture costs; change in contingent consideration; foreign currency loss/(gain); impairment of goodwill and intangible assets; gain on debt extinguishment; loss on divestiture; and, in applicable periods, certain other income and expense items, such as restructuring and reduction of force; income tax benefit; and deferred implementation costs. Adjusted Net Income (Loss) represents our Net Loss before stock-based compensation expense; foreign currency loss/(gain); acquisition, integration and divestiture costs (benefits); amortization of acquired intangibles; change in contingent consideration; impairment of goodwill and intangible assets; gain on debt extinguishment; and loss on divestiture, and in applicable periods, certain other income and expense items, such as restructuring and reduction of force and income tax benefit. We define Adjusted Net Income (Loss) per share as Adjusted Net Income (Loss) divided by our weighted-average common shares outstanding, diluted. We define Free Cash Flow as net cash provided by/(used in) operating activities, plus acquisition of property and equipment and capitalized software development costs. We believe Free Cash Flow is useful to measure the funds generated in a given period that are available for distribution or to sustain the business. We believe this supplemental information enhances stockholders' ability to evaluate our performance.

    We believe the use of non-GAAP financial measures, as a supplement to GAAP measures, is useful to investors in that they eliminate items that are either not part of our core operations or do not require a cash outlay, such as stock-based compensation expense. Management uses these non-GAAP financial measures when evaluating operating performance and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures help indicate underlying trends in the business, are important in comparing current results with prior period results and are useful to investors and financial analysts in assessing operating performance.

    We define MQUs as targetable customers that have made a transaction using their account with an FI Partner or other partners in a given month, excluding pilot supply during the ramp up period, and whose transaction data was shared with Cardlytics. We then calculate a monthly average of these MQUs for the periods presented. We believe that the number of MQUs is an indicator of the Cardlytics platform's ability to drive engagement and is reflective of the consumer base and insights that we offer to marketers. We define ACPU as the Cardlytics platform Adjusted Contribution generated in the applicable period, divided by Cardlytics average MQUs in the applicable period. We believe that Adjusted Contribution is the most relevant metric as it reflects the value Cardlytics keeps after subtracting out rewards, Partner Share and other third-party costs. We believe that ACPU measures the Cardlytics platform's efficiency in converting marketer budgets into the value generated by customer engagement.

     
     
     

    CARDLYTICS, INC.

    CONSOLIDATED BALANCE SHEETS

    (Amounts in thousands, except par value amounts)
     

     

     

    December 31,

     

     

    2025

     

     

     

    2024

     

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    48,719

     

     

    $

    65,594

     

    Accounts receivable and contract assets, net

     

    82,669

     

     

     

    103,252

     

    Other receivables

     

    2,587

     

     

     

    3,801

     

    Prepaid expenses and other assets

     

    3,304

     

     

     

    5,336

     

    Total current assets

     

    137,279

     

     

     

    177,983

     

    Long-term assets:

     

     

     

    Property and equipment, net

     

    2,025

     

     

     

    2,596

     

    Right-of-use assets under operating leases, net

     

    4,947

     

     

     

    6,341

     

    Intangible assets, net

     

    5,553

     

     

     

    11,371

     

    Goodwill

     

    110,305

     

     

     

    159,429

     

    Capitalized software development costs, net

     

    24,214

     

     

     

    33,341

     

    Other long-term assets, net

     

    1,318

     

     

     

    1,650

     

    Total assets

    $

    285,641

     

     

    $

    392,711

     

    Liabilities and stockholders' (deficit) equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    3,360

     

     

    $

    3,689

     

    Accrued liabilities:

     

     

     

    Accrued compensation

     

    6,105

     

     

     

    5,494

     

    Accrued expenses

     

    7,725

     

     

     

    7,175

     

    Partner Share liability

     

    24,860

     

     

     

    32,479

     

    Consumer Incentive liability

     

    32,144

     

     

     

    45,513

     

    Deferred revenue

     

    2,589

     

     

     

    2,154

     

    Short-term debt

     

    —

     

     

     

    45,863

     

    Current operating lease liabilities

     

    1,607

     

     

     

    2,025

     

    Current contingent consideration

     

    —

     

     

     

    4,563

     

    Total current liabilities

     

    78,390

     

     

     

    148,955

     

    Long-term liabilities:

     

     

     

    Convertible senior notes, net

     

    168,850

     

     

     

    167,729

     

    Line of credit

     

    40,070

     

     

     

    —

     

    Long-term deferred revenue

     

    52

     

     

     

    —

     

    Long-term operating lease liabilities

     

    4,787

     

     

     

    6,034

     

    Total liabilities

     

    292,149

     

     

     

    322,718

     

    Stockholders' (deficit) equity:

     

     

     

    Common stock, $0.0001 par value—100,000 shares authorized and 54,514 and 51,257 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively

     

    10

     

     

     

    10

     

    Additional paid-in capital

     

    1,399,542

     

     

     

    1,366,958

     

    Accumulated other comprehensive income

     

    (1,996

    )

     

     

    3,601

     

    Accumulated deficit

     

    (1,404,064

    )

     

     

    (1,300,576

    )

    Total stockholders' (deficit) equity

     

    (6,508

    )

     

     

    69,993

     

    Total liabilities and stockholders' (deficit) equity

    $

    285,641

     

     

    $

    392,711

     

     
     
     

    CARDLYTICS, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (Amounts in thousands except per share amounts)
     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2024

     

    Revenue

    $

    56,095

     

     

    $

    73,997

     

     

    $

    233,273

     

     

    $

    278,298

     

    Costs and expenses:

     

     

     

     

     

     

     

    Partner Share and other third-party costs

     

    24,395

     

     

     

    33,285

     

     

     

    102,949

     

     

     

    127,761

     

    Delivery costs

     

    5,810

     

     

     

    7,979

     

     

     

    25,711

     

     

     

    29,643

     

    Sales and marketing expense

     

    7,524

     

     

     

    11,343

     

     

     

    39,478

     

     

     

    52,649

     

    Research and development expense

     

    7,965

     

     

     

    9,895

     

     

     

    39,765

     

     

     

    49,607

     

    General and administrative expense

     

    9,730

     

     

     

    13,770

     

     

     

    47,267

     

     

     

    56,482

     

    Acquisition, integration and divestiture costs

     

    561

     

     

     

    —

     

     

     

    561

     

     

     

    161

     

    Change in contingent consideration

     

    —

     

     

     

    100

     

     

     

    102

     

     

     

    210

     

    Impairment of goodwill and intangible assets

     

    —

     

     

     

    —

     

     

     

    58,843

     

     

     

    131,595

     

    Gain on divestiture

     

    —

     

     

     

    —

     

     

     

    (4,831

    )

     

     

    —

     

    Depreciation and amortization expense

     

    6,205

     

     

     

    5,940

     

     

     

    25,244

     

     

     

    25,689

     

    Total costs and expenses

     

    62,190

     

     

     

    82,312

     

     

     

    335,089

     

     

     

    473,797

     

    Operating loss

     

    (6,095

    )

     

     

    (8,315

    )

     

     

    (101,816

    )

     

     

    (195,499

    )

    Other income (expense):

     

     

     

     

     

     

     

    Interest expense, net

     

    (2,139

    )

     

     

    (1,694

    )

     

     

    (7,919

    )

     

     

    (5,553

    )

    Foreign currency (loss) gain

     

    (16

    )

     

     

    (5,581

    )

     

     

    6,247

     

     

     

    (1,269

    )

    Gain on debt extinguishment

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    13,017

     

    Total other (expense) income

     

    (2,155

    )

     

     

    (7,275

    )

     

     

    (1,672

    )

     

     

    6,195

     

    Loss before income taxes

     

    (8,250

    )

     

     

    (15,590

    )

     

     

    (103,488

    )

     

     

    (189,304

    )

    Net Loss

     

    (8,250

    )

     

     

    (15,590

    )

     

     

    (103,488

    )

     

     

    (189,304

    )

    Net Loss per share, basic and diluted

    $

    (0.15

    )

     

    $

    (0.31

    )

     

    $

    (1.95

    )

     

    $

    (3.91

    )

    Weighted-average common shares outstanding, basic and diluted

     

    54,318

     

     

     

    51,005

     

     

     

    53,114

     

     

     

    48,361

     

     
     
     

    CARDLYTICS, INC.

    STOCK-BASED COMPENSATION EXPENSE

    (Amounts in thousands)
     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

    2025

     

    2024

     

    2025

     

    2024

    Delivery costs

    $

    232

     

    $

    641

     

    $

    1,673

     

    $

    2,680

    Sales and marketing expense

     

    901

     

     

    1,877

     

     

    4,611

     

     

    10,017

    Research and development expense

     

    1,917

     

     

    2,926

     

     

    10,431

     

     

    14,957

    General and administrative expense

     

    2,462

     

     

    3,229

     

     

    11,414

     

     

    12,713

    Total stock-based compensation expense

    $

    5,512

     

    $

    8,673

     

    $

    28,129

     

    $

    40,367

     
     
     

    CARDLYTICS, INC.

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Amounts in thousands)
     

     

     

    Year Ended December 31,

     

     

    2025

     

     

     

    2024

     

    Operating activities

     

     

     

    Net Loss

    $

    (103,488

    )

     

    $

    (189,304

    )

    Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

     

     

     

    Credit loss expense

     

    2,134

     

     

     

    6,106

     

    Depreciation and amortization

     

    25,244

     

     

     

    25,689

     

    Amortization of financing costs charged to interest expense

     

    1,522

     

     

     

    1,633

     

    Amortization of right-of-use asset

     

    2,165

     

     

     

    2,187

     

    Impairment of goodwill and intangible assets

     

    58,843

     

     

     

    131,595

     

    Gain on debt extinguishment

     

    —

     

     

     

    (13,017

    )

    Gain on divestiture

     

    (4,831

    )

     

     

    —

     

    Stock-based compensation expense

     

    28,129

     

     

     

    40,367

     

    Change in contingent consideration

     

    102

     

     

     

    210

     

    Other non-cash expense (income), net

     

    (6,243

    )

     

     

    1,481

     

    Change in operating assets and liabilities:

     

     

     

    Accounts receivable and contracts assets, net

     

    20,643

     

     

     

    12,497

     

    Prepaid expenses and other assets

     

    1,803

     

     

     

    1,360

     

    Accounts payable

     

    179

     

     

     

    499

     

    Other accrued expenses

     

    (724

    )

     

     

    (6,644

    )

    Partner Share liability

     

    (8,208

    )

     

     

    (16,350

    )

    Customer Incentive liability

     

    (7,980

    )

     

     

    (7,133

    )

    Net cash provided by (used in) operating activities

     

    9,290

     

     

     

    (8,824

    )

    Investing activities

     

     

     

    Acquisition of property and equipment

     

    (480

    )

     

     

    (1,562

    )

    Capitalized software development costs

     

    (15,302

    )

     

     

    (17,736

    )

    Proceeds from divestitures, net of cash divested

     

    480

     

     

     

    552

     

    Net cash used in investing activities

     

    (15,302

    )

     

     

    (18,746

    )

    Financing activities

     

     

     

    Proceeds from issuance of debt

     

    56,000

     

     

     

    172,500

     

    Principal payments of debt

     

    (62,000

    )

     

     

    (199,303

    )

    Proceeds from termination of capped calls related to convertible notes

     

    —

     

     

     

    115

     

    Proceeds from issuance of common stock

     

    —

     

     

     

    48,645

     

    Settlement of contingent consideration

     

    (5,000

    )

     

     

    (14,167

    )

    Deferred equity issuance costs

     

    —

     

     

     

    (309

    )

    Debt issuance costs

     

    (122

    )

     

     

    (6,037

    )

    Net cash (used in) provided by financing activities

     

    (11,122

    )

     

     

    1,444

     

    Effect of exchange rates on cash, cash equivalents and restricted cash

     

    259

     

     

     

    (110

    )

    Net decrease in cash, cash equivalents and restricted cash

     

    (16,875

    )

     

     

    (26,236

    )

    Cash, cash equivalents, and restricted cash — Beginning of period

     

    65,594

     

     

     

    91,830

     

    Cash, cash equivalents, and restricted cash — End of period

    $

    48,719

     

     

    $

    65,594

     

     
     
     

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP REVENUE TO BILLINGS

    (Amounts in thousands)
     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

    2025

     

    2024

     

    2025

     

    2024

    Revenue

    $

    56,095

     

    $

    73,996

     

    $

    233,273

     

    $

    278,298

    Plus:

     

     

     

     

     

     

     

    Consumer Incentives

     

    38,041

     

     

    42,283

     

     

    151,685

     

     

    165,542

    Billings

    $

    94,136

     

    $

    116,279

     

    $

    384,958

     

    $

    443,840

     
     
     

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED CONTRIBUTION

    (Amounts in thousands)
     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

    2025

     

    2024

     

    2025

     

    2024

    Revenue

    $

    56,095

     

    $

    73,996

     

    $

    233,273

     

    $

    278,298

    Minus:

     

     

     

     

     

     

     

    Partner Share and other third-party costs

     

    24,395

     

     

    33,285

     

     

    102,949

     

     

    127,761

    Delivery costs(1)

     

    5,810

     

     

    7,979

     

     

    25,711

     

     

    29,643

    Gross Profit

     

    25,890

     

     

    32,732

     

     

    104,613

     

     

    120,894

    Plus:

     

     

     

     

     

     

     

    Delivery costs(1)

     

    5,810

     

     

    7,979

     

     

    25,711

     

     

    29,643

    Adjusted Contribution

    $

    31,700

     

    $

    40,711

     

    $

    130,324

     

    $

    150,537

    (1)

    Stock-based compensation expense recognized in delivery costs totaled $0.2 million and $0.6 million during the three months ended December 31, 2025 and 2024, respectively. Stock-based compensation expense recognized in consolidated delivery costs totaled $1.7 million and $2.7 million during the year ended December 31, 2025 and 2024, respectively.

     
     
     

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

    (Amounts in thousands)
     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2024

     

    Net Loss

    $

    (8,250

    )

     

    $

    (15,590

    )

     

    $

    (103,488

    )

     

    $

    (189,304

    )

    Plus:

     

     

     

     

     

     

     

    Interest expense, net

     

    2,139

     

     

     

    1,694

     

     

     

    7,919

     

     

     

    5,553

     

    Depreciation and amortization

     

    6,205

     

     

     

    5,940

     

     

     

    25,244

     

     

     

    25,689

     

    Stock-based compensation expense

     

    5,512

     

     

     

    8,673

     

     

     

    28,129

     

     

     

    40,367

     

    Acquisition, integration and divestiture costs

     

    561

     

     

     

    —

     

     

     

    561

     

     

     

    161

     

    Change in contingent consideration

     

    —

     

     

     

    100

     

     

     

    102

     

     

     

    210

     

    Foreign currency loss (gain)

     

    16

     

     

     

    5,581

     

     

     

    (6,247

    )

     

     

    1,269

     

    Impairment of goodwill and intangible assets

     

    —

     

     

     

    —

     

     

     

    58,843

     

     

     

    131,595

     

    Gain on debt extinguishment

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (13,017

    )

    Gain on divestiture

     

    —

     

     

     

    —

     

     

     

    (4,831

    )

     

     

    —

     

    Restructuring and reduction of force

     

    2,351

     

     

     

    —

     

     

     

    3,825

     

     

     

    —

     

    Adjusted EBITDA

    $

    8,534

     

     

    $

    6,398

     

     

    $

    10,057

     

     

    $

    2,523

     

     
     
     

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP NET LOSS TO ADJUSTED NET INCOME (LOSS) AND ADJUSTED NET INCOME (LOSS) PER SHARE

    (Amounts in thousands except per share amounts)
     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2024

     

    Net Loss

    $

    (8,250

    )

     

    $

    (15,590

    )

     

    $

    (103,488

    )

     

    $

    (189,304

    )

    Plus:

     

     

     

     

     

     

     

    Stock-based compensation expense

     

    5,512

     

     

     

    8,673

     

     

     

    28,129

     

     

     

    40,367

     

    Foreign currency loss (gain)

     

    16

     

     

     

    5,581

     

     

     

    (6,247

    )

     

     

    1,269

     

    Acquisition, integration and divestiture costs (benefits)

     

    561

     

     

     

    —

     

     

     

    561

     

     

     

    161

     

    Amortization of acquired intangibles

     

    1,455

     

     

     

    1,455

     

     

     

    5,818

     

     

     

    9,810

     

    Change in contingent consideration

     

    —

     

     

     

    100

     

     

     

    102

     

     

     

    210

     

    Impairment of goodwill and intangible assets

     

    —

     

     

     

    —

     

     

     

    58,843

     

     

     

    131,595

     

    Gain on debt extinguishment

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (13,017

    )

    Gain on divestiture

     

    —

     

     

     

    —

     

     

     

    (4,831

    )

     

     

    —

     

    Restructuring and reduction of force

     

    2,351

     

     

     

    —

     

     

     

    3,825

     

     

     

    —

     

    Adjusted Net Income (Loss)

    $

    1,645

     

     

    $

    219

     

     

    $

    (17,288

    )

     

    $

    (18,909

    )

    Weighted-average number of shares of common stock used in computing Adjusted Net Income (Loss) per share:

     

     

     

     

     

     

     

    GAAP weighted-average common shares outstanding, diluted

     

    54,318

     

     

     

    51,005

     

     

     

    53,114

     

     

     

    48,361

     

    Adjusted Net Income (Loss) per share, diluted

    $

    0.03

     

     

    $

    0.00

     

     

    $

    (0.33

    )

     

    $

    (0.39

    )

     
     
     

    CARDLYTICS, INC.

    RECONCILIATION OF NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES TO FREE CASH FLOW

    (Amounts in thousands)
     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2024

     

    Net cash provided by (used in) operating activities

    $

    13,010

     

     

    $

    2,979

     

     

    $

    9,290

     

     

    $

    (8,824

    )

    Plus:

     

     

     

     

     

     

     

    Acquisition of property and equipment

     

    (25

    )

     

     

    (123

    )

     

     

    (480

    )

     

     

    (1,562

    )

    Capitalized software development costs

     

    (2,532

    )

     

     

    (4,313

    )

     

     

    (15,302

    )

     

     

    (17,736

    )

    Free Cash Flow

    $

    10,453

     

     

    $

    (1,457

    )

     

    $

    (6,492

    )

     

    $

    (28,122

    )

     
     
     

    CARDLYTICS, INC.

    RECONCILIATION OF FORECASTED GAAP REVENUE TO BILLINGS

    (Amounts in millions)
     

     

     

    Q1 2026 Guidance

    Revenue

    $35.0 - $40.0

    Plus:

     

    Consumer Incentives

    $17.5 - $28.5

    Billings

    $57.5 - $63.5

     
     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260304946746/en/

    Public Relations:

    [email protected]

    Investor Relations:

    [email protected]

    Get the next $CDLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDLX

    DatePrice TargetRatingAnalyst
    10/11/2024$4.00In-line
    Evercore ISI
    8/16/2024$5.00Outperform → Market Perform
    Northland Capital
    8/15/2024$4.00 → $3.50Neutral → Underperform
    BofA Securities
    8/8/2024Buy → Hold
    Craig Hallum
    8/8/2024Buy → Hold
    Needham
    8/8/2024$18.00 → $5.00Buy → Hold
    Lake Street
    6/20/2024$11.00Neutral
    BofA Securities
    6/18/2024$14.00Outperform
    Northland Capital
    More analyst ratings

    $CDLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Gupta Amit

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    3/3/26 4:57:35 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    2/20/26 5:12:58 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Chief Executive Officer Gupta Amit converted options into 250,000 shares and sold $88,765 worth of shares (97,208 units at $0.91), increasing direct ownership by 30% to 659,644 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    2/18/26 6:16:51 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Cardlytics with a new price target

    Evercore ISI initiated coverage of Cardlytics with a rating of In-line and set a new price target of $4.00

    10/11/24 8:36:58 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics downgraded by Northland Capital with a new price target

    Northland Capital downgraded Cardlytics from Outperform to Market Perform and set a new price target of $5.00

    8/16/24 8:54:02 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Cardlytics from Neutral to Underperform and set a new price target of $3.50 from $4.00 previously

    8/15/24 7:18:52 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    SEC Filings

    View All

    SEC Form S-8 filed by Cardlytics Inc.

    S-8 - Cardlytics, Inc. (0001666071) (Filer)

    3/4/26 4:35:23 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form 10-K filed by Cardlytics Inc.

    10-K - Cardlytics, Inc. (0001666071) (Filer)

    3/4/26 4:27:51 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cardlytics, Inc. (0001666071) (Filer)

    3/4/26 4:05:19 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardlytics Announces Fourth Quarter and Full Year 2025 Financial Results

    Cardlytics, Inc. (NASDAQ:CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2025. "In 2025, we took several steps to reset our business and improve our financial health," said Amit Gupta, CEO of Cardlytics. "Going forward, we remain well positioned to execute our mandate and deliver for our partners and advertisers, even as we navigate a decrease in MQUs following the conclusion of our Bank of America campaigns in January. We are moving forward with sharper focus and discipline to control our own destiny by prioritizing our initiatives that build on our core fundamental strengths." "It has been reinvigorating to rejoin the Cardlytics team," s

    3/4/26 4:02:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Timing of Its Fourth Quarter and Full Year 2025 Earnings Release

    Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the fourth quarter and full year ending December 31, 2025 will be released on March 4, 2026, after market close. Conference Call Details: When: March 4, 2026 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be available on the website. Dial-in: Call participants may dial +1 800-549-8228 and use Conference ID: 74668. About Cardlytics Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' firs

    2/19/26 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    PAR Technology to Acquire Bridg, Bringing Loyalty and Non‑Loyalty Data Together for Smarter Retail and Restaurant Activation

    Acquisition will accelerate PAR's roadmap for consumer data, loyalty, and media innovation PAR Technology Corporation (NYSE:PAR), a leading global foodservice technology provider, today announced that it has agreed to acquire the identity resolution and shopper intelligence platform Bridg, a division of Cardlytics, Inc. (NASDAQ Global Market: CDLX). The transaction is structured as an acquisition of substantially all Bridg assets. The purchase price is $27.5 million, subject to purchase price adjustments with a maximum total purchase price of $30.0 million, and is payable in shares of PAR Technology common stock. PAR Technology will also assume certain liabilities associated with the acqu

    1/26/26 8:02:00 AM ET
    $CDLX
    $PAR
    Computer Software: Programming Data Processing
    Technology
    Office Equipment/Supplies/Services
    Miscellaneous

    $CDLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hill Scott A bought $143,200 worth of shares (40,000 units at $3.58) (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:46:37 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Hornsey Liane bought $35,900 worth of shares (10,000 units at $3.59) (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:45:56 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Klinck John L. Jr. bought $48,860 worth of shares (14,000 units at $3.49), increasing direct ownership by 26% to 67,593 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:39:19 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Leadership Updates

    Live Leadership Updates

    View All

    Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer

    Cardlytics Inc. (NASDAQ:CDLX) today announced the appointment of David Evans as its new Chief Financial Officer, effective January 12, 2026. Evans is returning to Cardlytics, having previously held several executive roles including Chief Financial Officer and Chief Administrative Officer. As the returning Chief Financial Officer, Evans will oversee Cardlytics' finance, accounting, and investor relations functions as the company continues to execute against its longer-term growth vision. Evans rejoins Cardlytics after his initial tenure from 2014 to 2020, during which he helped guide the company through its earlier years of growth and a successful IPO in 2018. Evans is a seasoned executive

    12/18/25 8:10:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    TTV Capital Adds Lynne Laube and Rachel Hamilton as Venture Partners

    Co-founder and CEO of Cardlytics, Greenlight CMO to Provide Decades of Operational and Marketing Expertise to Portfolio Companies as Firm Enters 25th Year of Fintech Investing ATLANTA, April 30, 2025 /PRNewswire/ -- TTV Capital, an early-stage fintech venture capital firm, today announced that Lynne Laube and Rachel Hamilton have joined as venture partners. In these roles, Lynne and Rachel will provide strategic counsel to TTV Capital's portfolio companies based on their decades of experience scaling early-stage fintech companies. Today's news arrives as TTV Capital marks its 25th year of investing from its home base in Atlanta, the center of the fintech ecosystem. "We started investing in

    4/30/25 9:00:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    23andMe Appoints Three New Independent Directors to Board

    SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

    10/29/24 7:30:00 AM ET
    $ANSS
    $CDLX
    $LSCC
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Semiconductors

    $CDLX
    Financials

    Live finance-specific insights

    View All

    Cardlytics Announces Fourth Quarter and Full Year 2025 Financial Results

    Cardlytics, Inc. (NASDAQ:CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2025. "In 2025, we took several steps to reset our business and improve our financial health," said Amit Gupta, CEO of Cardlytics. "Going forward, we remain well positioned to execute our mandate and deliver for our partners and advertisers, even as we navigate a decrease in MQUs following the conclusion of our Bank of America campaigns in January. We are moving forward with sharper focus and discipline to control our own destiny by prioritizing our initiatives that build on our core fundamental strengths." "It has been reinvigorating to rejoin the Cardlytics team," s

    3/4/26 4:02:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Timing of Its Fourth Quarter and Full Year 2025 Earnings Release

    Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the fourth quarter and full year ending December 31, 2025 will be released on March 4, 2026, after market close. Conference Call Details: When: March 4, 2026 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be available on the website. Dial-in: Call participants may dial +1 800-549-8228 and use Conference ID: 74668. About Cardlytics Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' firs

    2/19/26 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Third Quarter 2025 Financial Results

    Cardlytics, Inc. (NASDAQ:CDLX), a commerce media platform, today announced financial results for the third quarter ended September 30, 2025. "In Q3, we've taken decisive action that we believe will reset our business, improve our financial health, and set ourselves on a viable path to return to growth," said Amit Gupta, CEO of Cardlytics. "We are moving forward with sharper focus and discipline, prioritizing initiatives that build on our fundamental strengths and where we believe we can win. Our mandate is clear – continue to deliver for our partners and advertisers, strengthen what differentiates us, and unlock long-term value for our shareholders." Third Quarter 2025 Financial Results

    11/5/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cardlytics Inc.

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    7/2/24 7:05:14 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    3/29/24 5:05:56 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    3/18/24 7:46:57 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology